[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"substance-related-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:substance-related-disorders":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,43,56,103,133,175,204,237,263,291,319,354,396,416,445,476,502,525,556,580,610,639,661],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053883","smart-r-substance-monitoring-and-active-relapse-tracking-repository-100053883",false,"NCT06676059","SMART-r: Substance Monitoring and Active Relapse Tracking Repository","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in the repository, an individual must meet all of the following criteria:\n\n* Must understand and be willing to complete an online informed consent process.\n* Be an adult aged 18 or older.\n* Self-report alcohol or other drug use within the past 30 days.\n* Have a smartphone as their primary mobile phone.\n\n  --For the AWARE app data monitoring procedure, there may be times during this study period where, due to technical or OS limitations, the app is only available to users of certain devices (e.g., Android, iOS). If there is such a limitation, this information will be evaluated during screening. For example, if the AWARE app is not available for iOS, then the screening form may exclude iPhone users for that time period where the limitation exists, if the only procedures offered are daily diary surveys and AWARE data monitoring.\n* Be willing to adhere to the procedures, such as downloading the AWARE app onto their smartphone and keeping it active throughout the data collection period, completing baseline questionnaires, daily diary EMAs, open-ended survey questions with the TTR Chatbot, uploading historical conversational AI data, and\u002For follow-up surveys.\n* Understand and write in English.\n\n  --This exclusion criterion is included because future research on the data collected will include linguistic analysis. all linguistic analyses, we remove rare words (e.g., words must be said by at least 95% of participants)95. Additionally, there are cultural differences across languages and, thus, interpreting language results across more than one language becomes difficult.96 As a result, we must keep analysis limited to a single language (English), since words in other languages will not meet that criteria.\n* Live in the United States.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this repository:\n\n1\\. Any impairment severe enough to preclude informed consent or valid self-report.","ALL","18 Years","120 Years",{"count":19,"type":20},10000,"ESTIMATED","OBSERVATIONAL","Background:\n\nAbout 1.5 million adults in the US enter alcohol or substance use treatment programs each year. Unfortunately, more than half of patients do not finish their program. For those who start treatment, about 70% return to substance use within weeks or months after starting treatment. To discover why patients drop out of treatment and return to substance use - and what can be done about it - researchers need to learn more about people who use drugs and alcohol.\n\nObjective:\n\nTo create a data repository by gathering survey and smartphone data from adults who use drugs and alcohol in order to conduct future research.\n\nEligibility:\n\nAdults who have used drugs or alcohol in the past and have a Android smartphone. The researchers will recruit targeted demographics at different times throughout the duration of the study period.\n\nDesign:\n\nData will be collected for up to 6 months. All research activities will be online.\n\nParticipants will download a smartphone app called TTRU-Curtis AWARE and keep it active on their phone. The app will run in the background and collect participant data, including: screen unlocks, duration of time the screen is on; apps used; words typed (except passwords); duration and time of phone calls; estimated location (exact location is not collected); and movement, such as how many steps are taken in a day. All personally identifying information is automatically removed before the data is stored (including phone numbers, names, or locations described in messages).\n\nEach day, participants will receive a text with a link to a survey. They will answer questions about their mood, behavior, and substance use from the day before. This survey should take less than 5 minutes to complete.\n\nEvery 30 days, participants will complete a longer survey. They will answer questions about their personal relationships, risky behaviors, mood, substance use, and feelings. They can skip any questions they do not feel comfortable answering. These surveys should take about 30 minutes to complete.\n\nParticipants may opt to allow researchers to access their social media posts.",[24,25],"Alcoholism","Substance-Related Disorders",[27,28,29],"Alcohol","Substance use","digital phenotyping","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":20},"2026-07-16",{"date":38,"type":20},"2044-12-31",{"name":40,"class":41},"National Institute on Drug Abuse (NIDA)","NIH",1,{"id":44,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":47,"keywords":48,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":55,"locationsCount":42},"100568042","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in the repository, an individual must meet all of the following criteria:\n\n* Must understand and be willing to complete an online informed consent process.\n* Be an adult aged 18 or older.\n* Self-report alcohol or other drug use within the past 30 days.\n* Have a smartphone as their primary mobile phone.\n* Be willing to adhere to the procedures, such as downloading the AWARE app onto their smartphone and keeping it active throughout the data collection period, completing baseline questionnaires, daily diary EMAs, uploading historical conversational AI data, and\u002For follow-up surveys.\n* Understand and write in English.\n\n  --This exclusion criterion is included because future research on the data collected will include linguistic analysis. all linguistic analyses, we remove rare words (e.g., words must be said by at least 95% of participants)95. Additionally, there are cultural differences across languages and, thus, interpreting language results across more than one language becomes difficult.96 As a result, we must keep analysis limited to a single language (English), since words in other languages will not meet that criteria.\n* Live in the United States.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this repository:\n\n1\\. Any impairment severe enough to preclude informed consent or valid self-report.",{"count":19,"type":20},[24,25],[27,28,29],"2026-07-01",{"date":51,"type":34},"2026-07-02",{"date":53,"type":20},"2026-07-07",{"date":38,"type":20},{"name":40,"class":41},{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":15,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100641150","launchpad-supporting-healthy-decisions-and-preventing-drug-use-after-high-school-100641150","NCT07655609","LaunchPad: Supporting Healthy Decisions and Preventing Drug Use After High School","Preventing Drug Use Onset and Progression Toward Addiction During a Critical Transition Period: Optimizing an Online Intervention for High School Seniors","Schools:\n\n* Public or private school in the U.S. enrolling 12th grade students\n* Agree to (1) provide us contact information for students and parents (or to send study information to students and parents themselves), (2) identify a school contact person (typically a school counselor) who will work with us to carry out the study (recruitment, pretest survey, intervention deployment, posttest survey), and (3) either provide school time to complete the intervention or integrate the intervention into a class (e.g., as an out-of-class assignment)\n\nStudents:\n\n* Enrolled as a 12th grade student at one of the participating schools\n* Have not completed a previous version of the intervention before\n* Between the ages of 15 and 21 years of age",true,"15 Years","21 Years",{"count":67,"type":20},5000,"INTERVENTIONAL",[70],"NA","LaunchPad is an online substance use prevention program for high school seniors. The program is designed to help seniors develop skills and make informed decisions as they transition from high school to young adulthood.\n\nThe purpose of this clinical trial is to learn whether individual LaunchPad lessons improve the specific attitudes, intentions, and skills they are designed to address. For example, researchers will examine whether the stress management lesson increases students' intentions to use healthy ways of managing stress.\n\nThe main question this study aims to answer is: Does each individual LaunchPad lesson improve the specific outcomes it was designed to address?\n\nResearchers will compare students who receive a particular lesson with students who do not receive that lesson to determine whether the lesson changes the intended outcome.\n\nParticipants will:\n\n* Complete a brief baseline survey\n* Complete two introductory online lessons\n* Complete one or more randomly assigned LaunchPad lessons\n* Complete a brief follow-up survey\n\nAll surveys and lessons will be completed online.",[73,74,75,76],"Substance-related Disorders","Alcohol-Related Disorders","Tobacco Use Disorder","Marijuana Use",[78,79,27,80,81,82,83,84,85,86,87,88,89,90,91],"Adolescence","Adolescent and Young Adult","Behavior","Decision Making","Development","Expectancy","High School Student","Intervention","Marijuana","Schools","Substance Use Prevention","Transition out of high school","Multi-phase Optimization Strategy","Normative Education","NOT_YET_RECRUITING","2026-06-22",{"date":95,"type":34},"2026-06-25",{"date":97,"type":20},"2026-09-01",{"date":99,"type":20},"2029-04-30",{"name":101,"class":102},"Prevention Strategies, LLC","INDUSTRY",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":110,"minAge":16,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":68,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":132},"100644226","pre-pilot-wings-mhealth-to-improve-moud-uptake-in-women-experiencing-intimate-partner-violence-and-ptsd-100644226","NCT07665502","Pre-Pilot WINGS+++: mHealth to Improve MOUD Uptake in Women Experiencing Intimate Partner Violence and PTSD","Pre-Pilot WINGS +++ An Effectiveness Trial of Syndemic Mhealth Intervention to Increase MOUD Uptake Among Women Impacted by Intimate Partner Violence and PTSD","Inclusion Criteria:\n\n* Identify as a woman (cis-gender or transgender)\n* Aged 18 or older\n* Report use of non-prescribed opioids in the past 30 days\n* Score positive for risk of opioid use disorder or other substance use disorder on the Drug Abuse Screening Test (DAST) with a cut-off score of 6 or higher\n* Report experiencing any severe psychological abuse or any physical or sexual abuse by a female or male intimate partner in the past year\n\nExclusion Criteria:\n\n* Evidence of significant psychiatric or cognitive impairment that would limit effective participation, as confirmed during informed consent\n* Inability to speak and understand English sufficiently to participate in assessments or intervention sessions","FEMALE",{"count":112,"type":20},7,[70],"The goal of this pre-pilot for the clinical trial is to develop a mobile health (mHealth) program called WINGS+++ can help women with opioid use disorder or other substance use disorders who have experienced intimate partner violence. The pre-pilot study will take place in Orange County, New York with n=7 women. .\n\nThe main questions it aims to answer are:\n\n1. Does WINGS+++ lower non-prescription opioid and other drug use in women?\n2. Does WINGS+++ help connect women to treatment for substance use, intimate partner violence, and post-traumatic stress disorder (PTSD)?\n\nResearchers will compare WINGS+++ to standard care to see if WINGS+++ works better to lower drug use and link women to helpful services.\n\nWINGS+++ is a 3-session program on a mobile device that:\n\n* Screens for intimate partner violence, PTSD, and substance use\n* Offers brief support and referrals based on each woman's needs and preferences\n* Connects women to a peer navigator who helps link them to services\n\nParticipants will:\n\n* Take part in only the WINGS+++ program for the pre-pilot\n* Answer survey questions about drug use, intimate partner violence, and PTSD symptoms\n* Provide biological samples (such as urine or hair) to check for drug use\n* Share information about the services they have used",[116,25,117,118,119,120,121],"Opioid-Related Disorders","Intimate Partner Violence (IPV)","Stress Disorders, Post-Traumatic","Domestic Violence","Medication for Opioid Use Disorder (MOUD)","Post Traumatic Stress Disorder PTSD","2026-06-18",{"date":124,"type":34},"2026-06-24",{"date":126,"type":20},"2026-06-15",{"date":128,"type":20},"2027-08-31",{"name":130,"class":131},"Dawn A. Goddard-Eckrich","OTHER",2,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":68,"phases":142,"briefSummary":143,"conditions":144,"keywords":153,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100509219","improving-alcohol-and-substance-use-care-access-outcome-equity-during-the-reproductive-years-100509219","NCT05910580","Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years","Improving Alcohol and Substance Use Care Access, Outcomes, and Equity During the Reproductive Years: A Type 1 Hybrid Trial in Family Planning Clinics","Inclusion Criteria:\n\n* Over the age of 18 years\n* U.S. residing\n* Have internet access (own a computer or smart phone)\n* Screen positive to one or more risky alcohol and substance use behaviors as determined by our standardized abbreviated instruments\n\nExclusion Criteria:\n\n* Not capable of communicating (reading, speaking, writing) in English or Spanish",{"count":141,"type":20},400,[70],"The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic.\n\nThe main questions it aims to answer are:\n\n* Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing?\n* Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity?\n* Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)?\n\nParticipants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months.\n\nResearchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.",[74,25,145,146,147,148,149,150,151,152],"Mental Health","Reproductive Health","Sexual Health","Sexually Transmitted Diseases","Contraception","Maternal Health","Pregnancy","Women's Health",[154,155,156,157,158,159,160,161,162,163,164,165],"Implementation Science","Mass Screening","Motivational Interviewing","Referral and Consultation","Quality of Health Care","Early Medical Intervention","Family Planning Services","Primary Health Care","Reproductive Health Services","Telemedicine","Preconception Care","Young Adult","2026-06-12",{"date":126,"type":34},{"date":169,"type":34},"2025-07-03",{"date":171,"type":20},"2027-05-31",{"name":173,"class":131},"Emory University",4,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":68,"phases":186,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":132},"100596953","prevention-of-relapse-in-behavioral-disorders-100596953","NCT07052175","Prevention of Relapse in Behavioral Disorders","Prevention of Relapse in Behavioral Disorders: Study Protocol of a Randomized Control Trial","PreCare","Inclusion Criteria:\n\n* Understand spoken and written Spanish.\n* Signing the informed consent.\n* Own a smartphone with internet access and an iOS or Android operating system.\n\nExclusion Criteria:\n\n* Institutionalized or incarcerated patients, or those anticipating imminent incarceration, without regular access to mobile phone use.\n* Refusal to install the mobile application.\n* Inability to understand and sign the informed consent form for any reason.","90 Years",{"count":185,"type":20},150,[70],"This study aims to validate the effectiveness of a digital tool for monitoring and early relapse detection in addiction treatment. It compares outcomes between a traditional multidisciplinary model and the same model enhanced by the technology. The research seeks to demonstrate the tool's added clinical value in improving long-term recovery outcomes.",[73],[190,191,192,193,194],"Substance use disorders","relapse prevention","multidisciplinary treatment","digital health","monitoring","2026-05-12",{"date":197,"type":34},"2026-05-14",{"date":199,"type":34},"2026-04-01",{"date":201,"type":20},"2026-12",{"name":203,"class":131},"Clínica Nuestra Señora de la Paz",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":63,"sex":15,"minAge":211,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":68,"phases":214,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":42},"100534228","evaluating-an-adverse-childhood-experience-targeting-advocate-model-of-a-substance-use-prevention-program-100534228","NCT06236100","Evaluating an Adverse Childhood Experience-Targeting Advocate Model of a Substance Use Prevention Program","Evaluating an Adverse Childhood Experience-Targeting Advocate Model of a Substance Use Prevention Program: A Hybrid Type 1 Effectiveness-Implementation Trial","Inclusion Criteria: To be eligible to participate in this study, a family must meet all of the following criteria:\n\n* Either reside in, or attend SFP meetings, within one of the 36 New Jersey communities with disproportionate levels of ACEs and substance use disorder (SUD) issues that are assigned to either the treatment or control conditions via the study's cluster randomized controlled trial design\n* Meet family eligibility requirements:\n\n  * One or more adult caregivers\n  * One or more adolescents, ages 7 to 17\n* Caregiver provision of signed and dated informed consent form\n* For children, informed assent and parental permission via the informed consent to participate in the study\n* Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study\n* Willingness to adhere to the regimens of the SFP and FA interventions\n* Access to necessary resources for participating in a technology-based intervention (i.e., computer, smart phone, internet access)\n\nExclusion Criteria: A family who meets any of the following criteria will be excluded from participation in this study:\n\n* Caregiver has previously completed SFP with one or more children, ages 7 to 17\n* Intellectual disabilities (i.e., cognitive impairments that would prohibit the completion of the SFP curriculum or data collection instruments)\n* Language difficulties (caregivers and children must read and understand spoken English)","7 Years",{"count":213,"type":20},360,[70],"Primary Objective: Conduct a rigorous evaluation of a prevention-based intervention designed to mitigate the harms of adverse childhood experiences (ACEs) exposure and prevent future ACEs, substance use, and overdose within 36 communities experiencing a disproportionate burden of substance use and ACEs.\n\nThe study has three aims: (1) use a cluster randomized controlled trial to test effectiveness of the Strengthening Families Program (SFP) + Family Advocate (FA) intervention on substance use, overdose, and ACEs in 18 communities compared with SFP-only in 18 communities; (2) conduct a robust process evaluation informed by the Consolidated Framework for Implementation Research (CFIR) to explore implementation barriers and facilitators; and (3) conduct a cost evaluation to accurately estimate the costs required to implement SFP and SFP+FA and assess the cost-effectiveness of SFP+FA relative to SFP alone. Findings will provide a roadmap about the best ways to help disproportionately affected communities prevent substance use, overdose, and ACEs.",[25,217],"Adverse Childhood Experiences",[217,219,220,221,222,223,224,225,226,227],"Strengthening Families Program","Family Advocate","Community-level interventions","Hybrid Type 1 Design","Mixed-Method Evaluation","Effectiveness Trial","Cluster Randomized Controlled Trial","Process Evaluation","Cost Evaluation","2026-04-29",{"date":230,"type":34},"2026-05-05",{"date":232,"type":34},"2023-11-29",{"date":234,"type":20},"2027-09-29",{"name":236,"class":131},"RTI International",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":68,"phases":247,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":42},"100443464","crp-and-sa-for-inpatient-veterans-100443464","NCT05054738","CRP and S&A for Inpatient Veterans","Impact of Combined Recovery Program and Home Telehealth Among Veterans With Substance Use Disorders in the VA Inpatient Setting","CRP and S&A","Inclusion Criteria:\n\n* Meeting DSM-V criteria for current SUD diagnosis of alcohol and\u002For illicit drug use disorder\n* Use of substances in past 30 days prior to date of index inpatient admission\n* Able to comprehend English\n* Able to provide informed consent\n* Functioning at an intellectual level sufficient to allow accurate completion of all assessments\n* Willing to commit to 6 group inpatient therapy sessions, telehealth S\\&A, as well as baseline, and 1-and 3-month follow-up assessments\n\nExclusion Criteria:\n\n* Auditory or visual impairment that would interfere with study procedures\n* Inability to speak or understand English\n* Acutely psychotic patients",{"count":246,"type":20},195,[70],"The purpose of this study is to evaluate how well three types of treatments work to improve the outcomes for people with substance use problems. Veterans admitted to the Charleston VA Psychiatric inpatient unit may be invited to participate. The three types of treatments that will be evaluated are:\n\n1. Combined Recovery Program (CRP), a six-session treatment group delivered on the inpatient unit.\n2. A Home Telehealth program, called Stable and Able (S\\&A), provided just prior to discharge and provides additional support for up to 3 months\n3. Treatment-as-usual (TAU), which is the treatment currently provided on the unit, consisting of various mental health topics and sessions designed to help with recovery.\n\nParticipation begins on the inpatient unit, beginning with CRP and\u002For TAU, and may continue with S\\&A post discharge. Participants will be followed up at 1 and 3- months post treatment.",[24,73,250],"Dual Diagnosis",[24,252,250],"Substance-related disorders","2026-04-27",{"date":255,"type":34},"2026-05-04",{"date":257,"type":34},"2022-09-06",{"date":259,"type":20},"2026-12-31",{"name":261,"class":262},"VA Office of Research and Development","FED",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":68,"phases":273,"briefSummary":274,"conditions":275,"keywords":280,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":174},"100514081","peer-recovery-to-improve-polysubstance-use-and-mobile-telemedicine-retention-100514081","NCT05973838","Peer Recovery to Improve Polysubstance Use and Mobile Telemedicine Retention","Peer-Delivered, Behavioral Activation Intervention to Improve Polysubstance Use and Retention in Mobile Telemedicine OUD Treatment in an Underserved, Rural Area","PRISM","Inclusion Criteria:\n\nPatient participants in the RCT must be 18 or older; receive OUD treatment as part of the telemedicine program; and exhibit polysubstance use within the past three-months (i.e., use of one or more non-prescribed substances (excluding opioids and\u002For tobacco) by urine toxicology or self-report.\n\nExclusion Criteria:\n\n* Demonstrating active, unstable or untreated psychiatric symptoms, including mania and\u002For psychosis that would interfere with study participation\n* Inability to understand the study and provide informed consent in English",{"count":272,"type":20},160,[70],"The purpose of this study is to evaluate the feasibility and effectiveness of a peer-led, brief, behavioral intervention to improve adherence to medication for opioid use disorder (MOUD) and reduce polysubstance use among patients with OUD and polysubstance use in underserved areas. The intervention is based on behavioral activation (BA) and is specifically designed to be implemented by a trained peer recovery specialist. In this hybrid, Type-1 effectiveness-implementation randomized controlled trial (RCT), the investigators will evaluate the effectiveness and implementation of Peer Activate vs. treatment as usual (TAU) over twelve months.",[276,277,278,279,25],"Polysubstance Addiction","Opioid Medication Assisted Treatment","Treatment Adherence","Retention in Care",[25,116,281,282],"Polysubstance Use","Mental disorders","2026-04-21",{"date":253,"type":34},{"date":286,"type":34},"2023-06-15",{"date":288,"type":20},"2027-09-01",{"name":290,"class":131},"University of Maryland, College Park",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":68,"phases":299,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":42},"100621028","testing-implementation-strategies-to-scale-up-a-multicomponent-continuum-of-service-intervention-for-families-involved-in-systems-with-parental-opioid-and-methamphetamine-use-100621028","NCT07365293","Testing Implementation Strategies to Scale-up a Multicomponent Continuum of Service Intervention for Families Involved in Systems With Parental Opioid and Methamphetamine Use","Inclusion Criteria:\n\n* Misuse of opioids and\u002For stimulants in the last year, including misuse of prescriptions\n* parent of a child aged 0-18 with the child living in the home or a reunification plan in place\n* residing in one of the nine participating counties\n* insured by Medicaid\n* access to a computer, smartphone, or wireless\u002Fcellular connection if a device were to be provided\n* Willing to enroll with the first available Just Care coach\n\nExclusion Criteria:\n\n\\-- Alcohol use disorder",{"count":298,"type":20},254,[70],"This study will explore how to expand the Just Care for Families (JCFF) program beyond its current sites in Oregon, while addressing two main challenges: the developer team cannot provide ongoing support to every new program, and rural counties face limits on caseloads and reimbursement because of long travel distances. To overcome these barriers, the trial will test two strategies-using a JCFF mobile app to improve outcomes and efficiency, and relying on trained Experts (instead of the developer team) to guide new counties. With five active counties and four new ones, researchers will study whether parents receiving JCFF with digital support show reduced opioid and stimulant use, better child welfare outcomes like reunification, and more efficient treatment. This study will also compare how well new counties implement JCFF compared to existing ones, and use modeling to see if digital tools help programs sustain themselves by balancing caseloads and reimbursement. This study is supported by and included in the Helping to End Addiction Long-term Initiative (https:\u002F\u002Fheal.nih.gov\u002F).",[302],"Substance Related Disorders",[304,305,306,307,308,309],"opioid","child welfare","prevention","evidence-based","implementation","stimulants","2026-04-14",{"date":312,"type":34},"2026-04-17",{"date":314,"type":34},"2026-02-12",{"date":316,"type":20},"2030-05-31",{"name":318,"class":131},"Chestnut Health Systems",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":15,"minAge":327,"maxAge":328,"enrollmentInfo":329,"targetDuration":4,"studyType":68,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":42},"100632971","evaluation-of-the-addpro-vocational-reintegration-program-add-pro-eval-100632971","NCT07520617","Evaluation of the ADD'Pro Vocational Reintegration Program (ADD-PRO-EVAL)","Evaluation of the ADD'Pro Program: A Partnership-Based Approach to Support Vocational Reintegration of Patients Receiving Addiction Care (ADD-PRO-EVAL)","ADD-PRO-EVAL","Inclusion Criteria:\n\n* Adult of working age (18 years or older)\n* Diagnosed substance use disorder receiving medical care\n* Unemployed or on sick leave with a vocational reorientation project\n* Motivated to work in the competitive labour market\n* Living in or wishing to work in the Puy-de-Dôme department (63), France\n* Legally authorised to work\n* Capable of providing written informed consent\n* Affiliated with a French social security scheme\n\nExclusion Criteria:\n\n* Medical care provided under a court-ordered treatment obligation\n* Previously included in the ADD'Pro program\n* Residing outside the Puy-de-Dôme with no plan to work in the department\n* Under legal guardianship (tutelle, curatelle, or sauvegarde de justice)\n* Deprived of liberty","16 Years","70 Years",{"count":330,"type":20},100,[70],"The goal of this clinical trial is to evaluate whether an integrated medico-psychosocial vocational support program (ADD'Pro) can improve employment outcomes in adults with substance use disorders receiving care at a specialized addiction day hospital.\n\nThe main question it aims to answer is:\n\n\\- Does participation in the ADD'Pro program increase the rate of competitive employment (at least one day worked in the open labour market) at 6 months compared to standard employment services?\n\nResearchers will compare participants enrolled in the ADD'Pro program to participants referred to conventional employment services (France Travail or Cap Emploi) to see if structured, dual medico-psychosocial support leads to higher rates of vocational reintegration, better employment preparation, improved quality of life, and reduced physiological stress reactivity.\n\nParticipants will:\n\n* Be randomly assigned to either the ADD'Pro program or standard employment services\n* If assigned to ADD'Pro: receive immediate individualised support from a vocational counsellor (CIP) at the CeCler Association, running in parallel with their hospital addiction care, with no fixed end date\n* If assigned to standard care: be referred to conventional employment services with monthly follow-up interviews at the hospital, and the option to join ADD'Pro after 6 months\n* Complete structured interviews and validated questionnaires at inclusion, 3, 6, and 12 months\n* A sub-sample of up to 50 participants will additionally take part in a simulated job interview stress test (adapted TSST) with salivary biomarker collection and heart rate monitoring at inclusion and 6 months",[334,335,336,337,338,339,340,341,342,302,343,344],"Addiction","Addiction Disorders","Substance Use Recovery","Return to Work","Recovery","Recovery Outcomes","Substance Use Disorder (SUD)","Employment, Supported","Employment","Vocational Rehabilitation","Substance Use (Drugs, Alcohol)","2026-04-02",{"date":347,"type":34},"2026-04-09",{"date":349,"type":20},"2026-04",{"date":351,"type":20},"2029-04",{"name":353,"class":131},"University Hospital, Clermont-Ferrand",{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":63,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":68,"phases":364,"briefSummary":365,"conditions":366,"keywords":371,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":42},"100581581","data2action-oregon-project-supporting-data-driven-decision-making-for-substance-use-services-policy-and-overdose-prevention-100581581","NCT06852170","Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention","Supporting Data-driven Decision-Making to Support Substance Use Service Expansion Policies and to Prevent Overdoses","D2A Oregon","Inclusion Criteria:\n\nSample 1: Local or Regional Decision Makers\n\n* At least 18 years old\n* Has decision-making authority within their professional role related to substance use service delivery, including leadership responsible for developing policy (e.g. executive directors) OR middle-managers (e.g., case managers, supervisor) and front-line workers responsible for service delivery decisions OR Responsible for developing local or state policy related to substance use\u002Fbehavioral health and\u002For the criminal justice system OR Advises these decision makers (e.g., legislative staff, data analysts)\n\nThese individuals will be drawn from organizations with the following perspectives: behavioral health, public health, health payer, first responders, health advocacy.\n\nSample 2: State or Local Decision Makers\n\n* At least 18 years old\n* Has decision-making authority within their professional role related to substance use service delivery, including leadership responsible for developing policy (e.g. executive directors) OR middle-managers (e.g., case managers, supervisor) and front-line workers responsible for service delivery decisions OR Responsible for developing local or state policy related to substance use\u002Fbehavioral health and\u002For the criminal justice system OR Advises these decision makers (e.g., legislative staff, data analysts)\n\nExclusion Criteria:\n\n* None.",{"count":363,"type":20},341,[70],"Oregon's decision makers (e.g., community service providers, public health, justice, advocacy groups, payers) are calling for comprehensive, current, and trusted data to inform how they allocate resources to improve substance use services and mitigate the growing opioid and methamphetamine epidemics in their state. Consistent with the HEAL Data2Action call for Innovation projects that drive action with data in real-world settings, this study will refine and test the impact of a novel implementation strategy to engage cross- sector decision makers and make data that they identify as relevant to their decisions available to them in easy- to-use products. The proposed study aims to not only address critical knowledge gaps regarding how and when data can inform impactful, transparent decision-making, but to provide decision makers with the data that they need to achieve community-wide substance use prevention and treatment goals, including the increased delivery of high-quality, evidence-informed, services and the prevention of overdoses.",[367,368,154,81,369,73,370],"Substance Abuse","Decision Making, Shared","Organizations","Policy",[372,373,374,367,154,375,252,376,370,368,369,377,378,379,380,381,382,116,383,384,385,386,387],"Health Services Research","Sequential","Stepped Wedge","Decision making","Substance abuse treatment centers","Focus Groups","Harm Reduction","Policy Making","Law Enforcement","User-Centered Design","Public Health","Naloxone","Methamphetamine","Health Disparate, Minority and Vulnerable Populations","Health Policy","Stakeholder engagement","2026-03-12",{"date":390,"type":34},"2026-03-16",{"date":392,"type":34},"2025-02-06",{"date":394,"type":20},"2028-08-31",{"name":318,"class":131},{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":68,"phases":404,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":42},"100476832","motivational-interviewing-at-intake-vs-intake-as-usual-on-client-engagement-in-addiction-treatment-100476832","NCT05489068","Motivational Interviewing at Intake vs Intake as Usual on Client Engagement in Addiction Treatment","Adapting Intake Procedures to Improve Treatment Delivery in Addiction Treatment","Inclusion Criteria (client participants):\n\n* English-speaking adults seeking treatment for alcohol or other drug use at one of two outpatient addiction treatment programs\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures\n* Physically withdrawn from alcohol or other drugs\n\nInclusion Criteria (personnel participants):\n\n* English-speaking adults currently employed at one of the two outpatient addiction treatment programs\n* Provision of electronic informed consent\n\nExclusion Criteria (client participants):\n\n* Experiencing severe withdrawal symptoms\n* Actively psychotic, manic, and\u002For suicidal\n\nExclusion Criteria (personnel participants):\n\n* current position: facility owner or clinical director",{"count":185,"type":20},[70],"This K23 study is an effectiveness-implementation hybrid type I design to determine the effectiveness of Motivational Interviewing at Intake (MII), relative to intake-as-usual on client engagement and mechanisms of engagement among adults seeking outpatient addiction treatment. We also will obtain personnel feedback on the feasibility of implementing MII into standard practice by having personnel from the addiction treatment study sites complete implementation climate measures before Motivational Interviewing (MI) training and post-clinical trial, as well as an individual interview on implementation feasibility post-trial.",[25,278],"2026-03-05",{"date":409,"type":34},"2026-03-09",{"date":411,"type":34},"2022-03-16",{"date":413,"type":20},"2026-12-01",{"name":415,"class":131},"University of New Mexico",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":68,"phases":424,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":444},"100545851","phase-3-optimizing-chronic-pain-care-with-mindfulness-and-chronic-pain-management-visits-100545851","NCT06387290","Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits","Inclusion Criteria:\n\n* Age 18 +\n* Current chronic pain diagnosis (pain for ≥3 months) determined by physician assessment\n* Prescribed long-term opioid therapy (≥3 months)\n* Score \\>=3 on the Pain Enjoyment General Activity scale\n* Score \\>=9 on the Current Opioid Misuse Measure OR lifetime psychiatric or substance use disorder diagnosis OR benzodiazepine use OR history of overdose OR patient or physician determination that risks of opioid use may outweigh the benefits of opioid use\n\nExclusion Criteria:\n\n* Chronic pain due to a cancer diagnosis\n* Active suicidal intent, schizophrenia, psychotic disorder\n* Prior experience with Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, Mindfulness-Based Relapse Prevention, or Mindfulness-Oriented Recovery Enhancement",{"count":423,"type":20},300,[425],"PHASE3","The primary aim of this implementation-effectiveness trial is to examine the effectiveness of Mindfulness-Oriented Recovery Enhancement (MORE) and patient-centered chronic pain management visits in primary care as interventions to reduce chronic pain, improve quality of life, and reduce opioid-related harms among chronic pain patients on long-term opioid therapy.",[428,429,25,430,431,432,433,116,434],"Chronic Pain","Prescription Opioid Misuse","Pain","Narcotic-Related Disorders","Chemically-Induced Disorders","Mental Disorders","Neurologic Manifestations","2026-01-30",{"date":437,"type":34},"2026-02-03",{"date":439,"type":34},"2025-02-25",{"date":441,"type":20},"2028-05-01",{"name":443,"class":131},"University of Utah",3,{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":15,"minAge":64,"maxAge":4,"enrollmentInfo":453,"targetDuration":455,"studyType":21,"phases":4,"briefSummary":456,"conditions":457,"keywords":461,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":474,"locationsCount":132},"100618340","alcohol-psychoactive-drugs-analgesics-and-evaluation-in-penetrating-abdominal-trauma-100618340","NCT07330349","Alcohol, Psychoactive Drugs, Analgesics and Evaluation in Penetrating Abdominal Trauma","Influence of Alcohol, Psychoactive Drugs, and Analgesic Administration on the Evaluation Process in Patients With Penetrating Abdominal Trauma","DIRECT","Inclusion Criteria:\n\n* Patients presenting to the emergency department with penetrating abdominal trauma.\n* Age 14 years or older.\n* Patients evaluated and managed according to standard trauma care protocols, including immediate operative management or clinical observation with serial physical examination, as clinically indicated.\n* Patients admitted to the participating trauma centers during the study period.\n\nExclusion Criteria:\n\n* Patients transferred from another institution after initial surgical intervention.\n* Patients declared dead on arrival.\n* Patients with incomplete or missing clinical data precluding assessment of outcomes of interest.",{"count":454,"type":20},363,"28 Days","This prospective observational study aims to evaluate whether alcohol consumption, psychoactive drug use, or prior administration of analgesics affects the clinical evaluation and surgical decision-making process in patients with penetrating abdominal trauma.\n\nThe study will be conducted in two level I trauma centers in Cali, Colombia: a public university hospital and a private university hospital, both with high volumes of trauma patients and established protocols for non-operative management using serial physical examination.\n\nIn many trauma centers, serial physical examination is used to safely identify patients who require surgical intervention. However, there is concern that intoxication or altered mental status may reduce the reliability of physical examination, potentially leading to unnecessary imaging studies, delays in surgical decision-making, or non-therapeutic laparotomies. Despite this concern, available evidence supporting these assumptions is limited.\n\nPatients older than 14 years with penetrating abdominal trauma who undergo clinical evaluation to decide on surgical intervention. Patients will be classified according to the presence or absence of alcohol consumption, psychoactive substance use, or prior analgesic administration. The primary outcome is the time from hospital admission to the decision for surgical intervention. Secondary outcomes include trauma severity, need for surgery, length of hospital and intensive care unit stay, complications, and mortality.\n\nBy comparing patients with and without substance exposure across two different trauma care settings, this study seeks to determine whether serial physical examination remains a reliable and safe method for clinical decision-making in this population. The results may help optimize evaluation strategies, reduce unnecessary surgical procedures and diagnostic tests, and improve the standardization of care for patients with penetrating abdominal trauma.",[458,459,73,460],"Abdominal Injuries","Alcohol Intoxication","Penetrating Abdominal Trauma",[462,463,464,465,466,467],"Trauma decision making","Time to surgery","Penetrating abdominal trauma","Alcohol use","Psychoactive substances","Analgesic administration","2025-12-29",{"date":470,"type":34},"2026-01-09",{"date":472,"type":34},"2020-11-25",{"date":435,"type":20},{"name":475,"class":131},"Fundacion Clinica Valle del Lili",{"id":477,"slug":478,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":63,"sex":110,"minAge":16,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":68,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":42},"100497921","understanding-the-role-of-doulas-in-supporting-people-with-pmads-100497921","NCT05763537","Understanding the Role of Doulas in Supporting People With PMADs","Inclusion Criteria:\n\n* Participants must be over the age of 18\n* Currently pregnant and between 13 and 26 gestational weeks at the time of enrollment\n* Live in a HRSA-designated rural area of Montana\n\nExclusion Criteria:\n\n* They are under the age of 18\n* Not currently pregnant\n* Not between 13-26 gestational weeks at the time of enrollment\n* If they do not live in a HRSA-designated rural are of Montana.",{"count":483,"type":20},75,[70],"Detailed Description The doula-led intervention developed during the first phase of this project will be pilot tested for feasibility. Following the recruitment procedures described in the recruitment and retention plan, approximately 75 participants will be enrolled into the study. Twenty-five of the participants will receive regular doula care and 25 of the participants will receive care from a doula trained in the PMAD doula training throughout their pregnancy, childbirth, and postpartum time period, following the intervention procedures developed in Aim 2 of this study. Twenty-five women will not receive care from a doula and will receive perinatal care as usual. Women in all groups will take surveys via REDCap during their enrollment in the intervention, at 1 month postpartum, 3 months, and 6 months postpartum (at the conclusion of the intervention). All participants who receive the PMAD doula intervention will complete checklists after each session with their doula, to assess fidelity to the intervention. Participant communication with their doula via patient notebook will also be assessed for fidelity to the intervention.",[150,151,487,488,489,145,25,490,491,492],"Delivery, Obstetric","Self Efficacy","Social Support","Postpartum Depression","Depression","Mental Health Services","2025-11-12",{"date":495,"type":34},"2025-11-14",{"date":497,"type":34},"2024-11-26",{"date":499,"type":20},"2026-07-31",{"name":501,"class":131},"University of Montana",{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":15,"minAge":509,"maxAge":328,"enrollmentInfo":510,"targetDuration":4,"studyType":68,"phases":512,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":42},"100507376","phase-2-transdermal-rotigotine-as-adjunct-to-behavioral-therapy-for-cocaine-use-disorder-100507376","NCT05886582","Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder","Phase 2a Double-Blind Placebo-Controlled Trial of Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder","Inclusion Criteria:\n\n* Male or female subjects between 25 and 70 years of age.\n* Meet current DSM-5 criteria for Cocaine Use Disorder (CocUD), moderate or severe\n* Able to understand and comply with study procedures\n* Have positive urine result for cocaine metabolite benzoylecgonine (BE) during at least one screening visit (out of up to three visits, depending on participants' preference) AND\u002FOR self-report of recent cocaine use (approximately past 30 days).\n* Have hematology and chemistry laboratory tests that are within normal limits, except that liver function tests must be no more than 2x of the upper limit of normal (if any elevation is above the limit - must be judged by the study physician to be clinically insignificant).\n* No clinically significant abnormalities on baseline ECG.\n* Be able to demonstrate an understanding of study procedures and follow instructions including behavioral laboratory and fMRI testing.\n* Women must either be unable to conceive (i.e., surgically sterilized, sterile, or postmenopausal) or be using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device with spermicide, or condoms). Men will be advised to use condoms. All females must provide negative pregnancy urine tests before study entry, at each visit during the study, and the end of study participation.\n* Body Mass Index (BMI) between 18-45kg\u002FM2 and weight of at least 50kg at screening\n\nExclusion Criteria:\n\n* Have concurrent secondary DSM-5 diagnosis of any psychoactive substance use disorder other than cocaine, alcohol, methamphetamine, nicotine, opioid, or marijuana use disorder.\n* Have a DSM-5 axis I psychiatric disorder other than substance use disorder, including but not limited to Bipolar I Disorder, Schizophrenia, or other psychotic disorder that require treatment with antipsychotics, or a neurological disorder requiring ongoing treatment and\u002For making study participation unsafe. Comorbid PTSD, Generalized Anxiety Disorder and Major Depressive Disorder will be allowed.\n* Consistent and regular (as opposed to intermittent, infrequent, or as needed) use of medications contraindicated for concurrent use along with RTG, or would confound the mechanism of RTG action and data interpretation. These include DA antagonists such as antipsychotic medications (especially neuroleptics) or metoclopramide.\n* Subjects with evidence or history of any clinically significant medical disorder including biliary obstruction, clinically significant hepatic disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal, or endocrine disease. However, controlled hypertension, controlled hypothyroidism, and cancer in remission over 5 years will not be excluded.\n* Have a history of seizures (excluding childhood febrile seizures) or loss of consciousness (e.g. from traumatic brain injury) for more than 30 minutes.\n* Have significant current suicidal or homicidal ideation or a suicide attempt within the past 6 months, based on the Columbia Suicide Severity Rating Scale (C-SSRS).\n* Be HIV positive by self-report or history.\n* Be pregnant or nursing or not using a reliable form of contraception if able to conceive. All females must provide negative pregnancy urine tests before study entry, at each visit during the study, and the end of study participation\n* Have any other illness, or condition, which in the opinion of the clinical co-investigator (Arias) would preclude safe and\u002For successful completion of the study.\n* Be allergic to rotigotine.\n* Have taken any investigational drug within 45 days prior to baseline\n* Demonstrate intolerance to, poor adherence to, or extreme skin irritation by daily application of known placebo \"practice\" skin patches during the screening phase\n* Current\u002Fpending criminal charges that may result in incarceration within the next 60 days\n* Self-report of allergic or other reactions to sulfites (e.g. in foods)","25 Years",{"count":511,"type":20},40,[513],"PHASE2","This is a randomized, double-blind, placebo-controlled phase 2b pilot clinical trial to determine whether non-ergoline D3\u002FD2\u002FD1 dopamine (DA) receptor agonist rotigotine (RTG), in combination with treatment as usual, including individual or group behavioral therapy can a) reduce cocaine use and also b) increase brain activity in frontocortical areas of the brain, and, as a reflection of that - improve top-down cognitive control in persons with cocaine use disorder (CocUD).\n\nRotigotine is a marketed non-ergoline D3\u002FD2\u002FD1 DA agonist (RTG, Neupro®) in the form of a transdermal patch that is FDA-approved for the treatment of Parkinson's Disease and Restless Legs Syndrome. The premise of this project was based on apparent beneficial effects of RTG in a different human population characterized by executive function (EF) impairment. In light of the deficits in EF common in persons with CocUD, RTG may hold the potential for cognitive improvement in persons with CocUD who are in treatment as usual to both attend to and retain psychoeducation concepts better. In addition, rotigotine may help these individuals in recovery maintain goals better, where goal maintenance is a crucial integrative product of successful EF.",[25],"2025-09-25",{"date":518,"type":34},"2025-09-29",{"date":520,"type":34},"2023-09-11",{"date":522,"type":20},"2026-06",{"name":524,"class":131},"Virginia Commonwealth University",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":531,"enrollmentInfo":532,"targetDuration":4,"studyType":68,"phases":534,"briefSummary":535,"conditions":536,"keywords":541,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":444},"100558236","phase-2-glp-1r-agonist-treatment-for-opioid-use-disorder-100558236","NCT06548490","GLP-1R Agonist Treatment for Opioid Use Disorder","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* Body mass index (BMI) \\> 18.\n* Able and willing to provide informed consent prior to any study-related activities.\n* Current diagnosis of Diagnostic and Statistical Manual Diploma in Social Medicine (DSM)-5 Opioid Use Disorder (OUD) as per the Mini International Neuropsychiatric Interview (MINI) or per the site clinic diagnosis. Patients are eligible if they have a MINI \\> 3 (\"moderate\" or \"severe\" in the \"Specify If\" box in the Substance Use Disorder (Non-Alcohol) module for the category of opiates).\n* Currently receiving outpatient treatment for OUD and at least 2 weeks on buprenorphine (BUP) or 4 weeks on methadone at the study site and\u002For at an associated clinic at the time of enrollment.\n* Have at least 1 urine test positive for opioids after 2 weeks on BUP or 4 weeks on methadone.\n* Have positive self-reporting of opioid use after 2 weeks on BUP or 4 weeks on methadone.\n* If anatomically capable of becoming pregnant and of childbearing age, is not pregnant (confirmed) or breastfeeding at the time of enrollment and agrees to use a medically accepted method of birth control or to abstain from sexual intercourse while in the study.\n* Able to read and communicate in English to the level required to accept standard care and complete all study requirements.\n* Able and willing to engage\u002Fadhere to the entirety of the study protocol (19 weeks).\n* Not currently a prisoner.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 75 years.\n* BMI \\\u003C18.\n* Individuals who are pregnant, planning pregnancy, breastfeeding, or unwilling to use adequate contraceptive measures.\n* Current use of glucagon-like peptide 1 receptor (GLP-1R) agonist.\n* History of angioedema, serious hypersensitivity reaction, or anaphylactic reaction to semaglutide or another GLP-1R agonist.\n* Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome Type 2 (MEN 2) or thyroid nodule.\n* Type 1 diabetes or history of diabetic ketoacidosis.\n* Type 2 diabetes mellitus or current use of a dipeptidyl peptidase-4 (DPP-4) inhibitor.\n* Past 30-day use of Sincalide, Sulfonylureas, insulin and insulin products or other medications that may interact with semaglutide.\n* Hypoglycemia on intake visit (blood glucose \\\u003C 60 mg\u002FdL).\n* End-stage renal failure, on dialysis, or glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin per 1.73 square meters or previous renal transplant.\n* End stage liver disease or previous liver transplant.\n* Current or past diagnosis of pancreatitis, gastroparesis, or other severe gastrointestinal (GI) disease.\n* Current or past diagnosis of gallbladder disease or gallstones.\n* Serious cardiovascular disease within the past 6 months (e.g. uncontrolled hypertension, heart failure, significant cardiac arrhythmias, myocardial infarction, presence of angina pectoris, symptomatic coronary artery disease, deep vein thrombosis, pulmonary embolism, second- or third-degree heart block, mitral valve or aortic stenosis, hypertrophic cardiomyopathy, stroke).\n* Severe co-occurring psychiatric disorder (e.g., bipolar disorder, psychotic disorder, schizophrenia), and\u002For history or evidence of organic brain disease or dementia that would compromise safety or compliance with the study protocol in the opinion of the site principal investigator (PI) and\u002For physician. As there is no specific scale that determines this, this will include the Site PI\u002Fphysician determining if the potential participant shows consistency in decision making and if they are alert and oriented to time, date, day and location.\n* Significant risk of suicide requiring a different\u002Fhigher level of care, according to the clinical judgment of the study physician or site principal investigator, or history of suicide attempts within the past 1 year, unless participation is cleared by clinician assessment and\u002For judgment. A Columbia-Suicide Severity Rating Scale (C-SSRS) indicating a history of suicide attempts within the past year, or active suicidal ideation within the past 1 month, will qualify as significant risk of suicide.\n* Treatment with any investigational drug in the one month preceding the study.\n* Any contraindication to both methadone and BUP.\n* Any contraindication to a GLP-1R agonist.\n* Previous randomization for participation in this trial.\n* Any other condition at screening that precludes safe participation in the trial in the judgment of the site PI or study physician.\n* Plans for travel outside of the local area over the 19 weeks (1 week of baseline, 12 weeks of medication, 1 week wash-out, and follow-up after a further 28 days) that would interfere with visits during the study period or other logistic factors that would make it difficult to commit to the entire duration of study.\n* Currently a prisoner.","75 Years",{"count":533,"type":20},200,[513],"The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is:\n\n• Does semaglutide increase the likelihood that participants will refrain from using illicit and nonprescribed opioids?\n\nThe investigators will compare semaglutide to a placebo (a needle prick that contains no drug) to see if semaglutide works to reduce use of illicit and nonprescribed opioids.\n\nThe participants will:\n\n* Take semaglutide or a placebo every week for 12 weeks\n* Visit the clinic every week for urine drug screening and pregnancy testing, vital signs, and to complete mental health and drug use questionnaires\n* Complete smartphone surveys sent at set times during the study",[537,538,431,25,432,539,540],"Opioid Use Disorder","Opioid Abuse and Addiction","Mental Disorder","Opioid",[542,543,544,545,546],"Opiate treatment","Opioid treatment","Glucagon-Like Peptide-1 Agonist","Opioid use disorder","Semaglutide","2025-08-11",{"date":549,"type":34},"2025-08-14",{"date":551,"type":34},"2025-01-13",{"date":553,"type":20},"2026-11",{"name":555,"class":131},"Milton S. Hershey Medical Center",{"id":557,"slug":558,"hasResults":11,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":564,"conditions":565,"keywords":568,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":42},"100373344","structured-physical-exercise-in-short-term-inpatient-treatment-of-substance-use-disorder-100373344","NCT04141202","Structured Physical Exercise in Short-term Inpatient Treatment of Substance Use Disorder","Structured Physical Exercise in Short-term Inpatient Treatment of Substance Use Disorder: Implications for Abstinence, Quality of Life, Physical- and Mental Health","Inclusion Criteria:\n\n* Being an inpatient at the clinic\n\nExclusion Criteria:\n\n\\-",{"count":533,"type":20},"In 2017, structured physical exercise with high intensity was implemented as a part of the treatment program at St. Olav Hospital Clinic of Substance Use and Addiction Medicine.\n\nThe objective of this study is to examine whether implementing structured physical exercise in the treatment program has implications for patients' physical and mental health and quality of life after completing a 3 month residential treatment program.\n\nThe results of this study will benefit substance use disorder patients in the future, and may have an impact on further implementation of physical exercise in addiction treatment clinics both nationally and internationally.",[25,566,567],"Drug Abuse","Drug Dependence",[569,570],"Exercise therapy","Exercise physiology","2025-06-04",{"date":573,"type":34},"2025-06-08",{"date":575,"type":34},"2020-02-25",{"date":577,"type":20},"2025-12-30",{"name":579,"class":131},"St. Olavs Hospital",{"id":581,"slug":582,"hasResults":11,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":587,"enrollmentInfo":588,"targetDuration":4,"studyType":68,"phases":590,"briefSummary":591,"conditions":592,"keywords":593,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":42},"100586544","comparing-combined-behavioral-intervention-and-ericksonian-hypnotherapy-for-alcohol-addiction-100586544","NCT06916754","Comparing Combined Behavioral Intervention and Ericksonian Hypnotherapy for Alcohol Addiction","Comparing the Efficacy of Combined Behavioral Intervention and Ericksonian Hypnotherapy in the Treatment of Alcohol Addiction: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged between 18 and 65 years\n* Meets DSM-5 diagnostic criteria for Alcohol Use Disorder (mild to severe)\n* Medically and psychiatrically stable as determined by a clinician\n* Willing and able to participate in weekly sessions over a 12-week period\n* Provides informed consent\n\nExclusion Criteria:\n\n* Current diagnosis of a severe psychiatric disorder (e.g., psychotic disorder, bipolar I disorder)\n* Significant cognitive impairment that would interfere with treatment participation\n* Participation in another structured addiction treatment during the study period\n* Current use of psychotropic medications that may influence outcome measures (as assessed by the clinical team)\n* Unstable medical condition requiring immediate intervention\n* Pregnancy or planning to become pregnant during the study period","65 Years",{"count":589,"type":20},90,[70],"This clinical study is being conducted to compare the effectiveness of two psychological treatments for alcohol addiction: Combined Behavioral Intervention (CBI) and Ericksonian Hypnotherapy (EH). The purpose of the study is to determine whether Ericksonian Hypnotherapy, a more personalized and indirect therapeutic method, is equal to or more effective than the gold-standard approach, Combined Behavioral Intervention, in helping individuals reduce their alcohol consumption and improve psychological well-being.\n\nAlcohol addiction is a serious condition that affects mental, emotional, and physical health. Many treatment options exist, but not all individuals respond in the same way. This study aims to evaluate two different types of therapy in a structured way, to better understand which works best, for whom, and under what circumstances.\n\nThe study will include 90 adult participants diagnosed with Alcohol Use Disorder (AUD). Participants will be randomly assigned to one of three groups: (1) a group receiving weekly sessions of Combined Behavioral Intervention, (2) a group receiving weekly sessions of Ericksonian Hypnotherapy, or (3) a control group receiving general educational materials about alcohol addiction. Treatment will last for 12 weeks, and all participants will be followed up three months after the last session to assess long-term effects.\n\nThroughout the study, researchers will measure changes in alcohol consumption, alcohol craving, mental health symptoms (such as depression and anxiety), quality of life, and motivation to change. The findings of this study may help improve the way alcohol addiction is treated by offering evidence on alternative approaches such as hypnotherapy.",[74,24,73],[594,595,596,156,597,598,599,600],"Ericksonian Hypnosis","Hypnotherapy","Cognitive Behavioral Therapy","Relapse Prevention","Craving","Substance Craving","Psychotherapy","2025-04-13",{"date":603,"type":34},"2025-04-16",{"date":605,"type":34},"2025-03-01",{"date":607,"type":20},"2026-02-01",{"name":609,"class":131},"Beykoz University",{"id":611,"slug":612,"hasResults":11,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":42},"100586891","development-of-the-drug-and-alcohol-respiratory-health-test-100586891","NCT06921278","Development of the Drug and Alcohol Respiratory Health Test","Psychometric Development of the Alcohol and Drug Respiratory Health Questionnaire and Evaluation of a Lung Health Clinic","DARHT","Inclusion Criteria:\n\n1. \\>18 (no upper age limit)\n2. Inhalation (smoking) of tobacco, or cannabis, or cocaine, or opioids, or use of alcohol in the past 28 days\n3. Possession of a personal mobile phone to arrange follow-up appointments\n\nExclusion Criteria:\n\n1. Reported physical health condition that would mean spirometry contra-indicated - including heart attack, unstable angina, pulmonary embolism,\n2. Reported surgery in the past 3 months for an eye, chest, or abdominal condition that would mean spirometry contra-indicated\n3. Likely inability to complete study due to criminal justice involvement with legal proceedings risking incarceration",{"count":619,"type":20},260,"The goal of this study is to develop a brief Drug and Alcohol Respiratory Health Test (DARHT) and offer it for routine use in clinical assessment and medical reviews",[622,25,623,624,625,626,627,628,629],"Respiratory Disease","COPD","Asthma","Lung Cancer","Tuberculosis","Bronchitis","Pneumonia","Obstructive Sleep Apnea","2025-04-03",{"date":632,"type":34},"2025-04-10",{"date":634,"type":20},"2025-04-15",{"date":636,"type":20},"2025-11-11",{"name":638,"class":131},"King's College London",{"id":640,"slug":641,"hasResults":11,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":4,"eligibilityCriteria":645,"healthyVolunteers":63,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":68,"phases":648,"briefSummary":649,"conditions":650,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":659,"locationsCount":42},"100568728","phase-ii-scalable-digital-delivery-of-craft-training-for-professionals-to-maximize-treatment-rates-of-oud-in-families-100568728","NCT06685003","Phase II: Scalable Digital Delivery of CRAFT Training for Professionals to Maximize Treatment Rates of OUD in Families","Phase II: Scalable Digital Delivery of Evidence-based Training for Addiction Professionals to Maximize Treatment Admission and Retention Rates of Opioid Use Disorder in Affected Families","Inclusion Criteria:\n\n* Be over 19\n* Live in the US\n* Work in a counselor-related profession\n* Have counseling work that involves clients\n* Work with CSOs impacted by OUD, or could work with this type of client\n* Have not been certified in CRAFT\n* Have not participated in the 2023 WTV counselor training pilot study\n* Be able to provide at least 45-minute individual counselor sessions to at least one CSO (CSO)\n* Be able and willing to complete intervention activities over the course of the 12-week study as determined by the random assignment including: participating in the tutorial and training and submitting the required session audiotapes\n* Report having access to a computer and smartphone with internet access, email, and word processing capability\n* Demonstrate complete understanding of the requirements for participation in the study by reading and signing the consent form and completing the online consent quiz or confirmation call\n* Provide valid locator information to allow research and CRAFT training staff to contact them to schedule study-related appointments\n* Complete the first assessment mock session with our standardized patient (SP) and pre-tutorial surveys\n\nExclusion Criteria:\n\n* Does not agree to participate\n* Does not complete the baseline assessment requirements\n* Is not English-speaking\n* Participated in the Qualitative Review aspect of the study",{"count":647,"type":20},240,[70],"The goal of this project is to demonstrate digital training efficacy at scale and commercial readiness.\n\nThis pilot project will advance piloted digital training programs for CRAFT and maximize scalability. In this project, investigators will:\n\nAim 1: Optimize the digital CRAFT training product based on data and feedback from the pilot and commercialization advisors.\n\nAim 2: Conduct a fully powered randomized control trial of 3 levels of digital training (Level 1 - Digital tutorial only \\[T\\]; Level 2 - Tutorial \\& digital training materials for self-study \\[TM\\]; Level 3 - Tutorial, digital materials, feedback and coaching \\[TMC\\]) to examine the effects of training on CRAFT knowledge, fidelity, and plus IP treatment entry\u002Fretention and counselor skill pre- and post-tutorial, at 12 weeks and at 6 months.",[651,652,25],"Community Reinforcement And Family Training","Family Health","2024-11-11",{"date":655,"type":34},"2024-11-12",{"date":657,"type":34},"2024-11-04",{"date":607,"type":20},{"name":660,"class":131},"We The Village, Inc.",{"id":662,"slug":663,"hasResults":11,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":667,"eligibilityCriteria":668,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":670,"conditions":671,"keywords":672,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":42},"100565222","the-road-to-recovery-initiative-r2ri-100565222","NCT06639373","The Road to Recovery Initiative (R2RI)","The Road to Recovery Initiative (R2RI): an Observational Study of a Novel Model of Substance Use Care in a Canadian Setting","R2RI","Inclusion Criteria:\n\n* Aged 18 years or older\n* Able to provide written informed consent\n* A resident of British Columbia\n* Willing to comply with study procedures\n* An individual who has accessed one or more R2R services\n\nExclusion Criteria:\n\n* Individuals who have an acute, severe mental health condition (e.g., psychosis) precluding the opportunity to provide full informed consent\n* Individuals who have an acute, severe medical condition (e.g., intubation) precluding the opportunity to provide full informed consent",{"count":19,"type":20},"Despite substance use causing significant harms and cost to our health care system, British Columbia's (BC) current addiction treatment system remains under-resourced and fragmented. To address this, Providence Health Care (PHC) is expanding clinical addiction services as part of the Road to Recovery Initiative (R2R). The proposed study aims to generate novel data to promote fully evidence-informed and coordinated substance use care in BC and beyond. This study will explore substance use treatment trajectories, identify challenges and areas for growth in addiction health services, characterize important features of patients accessing care, and improve our provincial capacity to promptly tailor approaches to care in response to the substance use crisis.",[25],[673,674,675,676,677],"addiction","substance use","alcohol","opioids","harm reduction","2024-10-10",{"date":680,"type":34},"2024-10-15",{"date":682,"type":34},"2023-10-05",{"date":684,"type":20},"2033-10-05",{"name":686,"class":131},"BC Centre on Substance Use"]